Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1

Status

Active not recruiting 3Terminated 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Thoracic 3Gastrointestinal 2Head & Neck 1Gynecologic 1

Conditions

Melanoma 5Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Specimen Handling 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
naporafenib × Dermatologic × Clear all
NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Novartis

Phase 2 Active not recruiting
134 enrolled
Dermatologic

Melanoma

NCT05907304 2026-02-27

SEACRAFT-1

Erasca, Inc.

Phase 1 Active not recruiting
86 enrolled
DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT06346067 2026-02-27

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Erasca, Inc.

Phase 3 Active not recruiting
78 enrolled
Dermatologic

Melanoma

NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Novartis

Phase 1 Terminated
241 enrolled
DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

NCT02607813 2022-12-21

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Novartis

Phase 1 Terminated
142 enrolled
DermatologicGynecologic

Melanoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡